The Amyloid-β Oligomer Hypothesis: Beginning of the Third Decade
Open accessThe DOI matches its Crossref record; 452 of the 457 references it cites were found in a registry or an index.
Abstract
The amyloid-β oligomer (AβO) hypothesis was introduced in 1998. It proposed that the brain damage leading to Alzheimer's disease (AD) was instigated by soluble, ligand-like AβOs. This hypothesis was based on the discovery that fibril-free synthetic preparations of AβOs were potent CNS neurotoxins that rapidly inhibited long-term potentiation and, with time, caused selective nerve cell death (Lambert et al., 1998). The mechanism was attributed to disrupted signaling involving the tyrosine-protein kinase Fyn, mediated by an unknown toxin receptor. Over 4,000 articles concerning AβOs have been published since then, including more than 400 reviews. AβOs have been shown to accumulate in an AD-dependent manner in human and animal model brain tissue and, experimentally, to impair learning and memory and instigate major facets of AD neuropathology, including tau pathology, synapse deterioration and loss, inflammation, and oxidative damage. As reviewed by Hayden and Teplow in 2013, the AβO hypothesis "has all but supplanted the amyloid cascade." Despite the emerging understanding of the role played by AβOs in AD pathogenesis, AβOs have not yet received the clinical attention given to amyloid plaques, which have been at the core of major attempts at therapeutics and diagnostics but are no longer regarded as the most pathogenic form of Aβ. However, if the momentum of AβO research continues, particularly efforts to elucidate key aspects of structure, a clear path to a successful disease modifying therapy can be envisioned. Ensuring that lessons learned from recent, late-stage clinical failures are applied appropriately throughout therapeutic development will further enable the likelihood of a successful therapy in the near-term.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig.1 AβOs, not Aβ monomers or fibrils, instigate the neuron damage leading to dementia. Following cleavage from the membrane, Aβ peptides aggregate to form AβOs, some of which further aggregate to fibrils and some of which instigate the neuron damage leading to dementia. Reprinted with Jannis Productions permissions from the “Progress Report on Alzheimer’s Disease 2004-2005” (ed. AB Rodgers), NIH Publication Number: 05-5724. Digital images produced by Stacy Jannis and Rebekah Fredenburg of Jannis Productions [455].](https://figures.cochat.ai/paper-figures/f6b42a17775e4881b942c99d83b0c0fa/the-amyloid-oligomer-hypothesis-beginning-of-the-third-decade-figure-1.jpg)
![Fig.2 AβOs instigate multiple facets of AD-neuropathology. Observed in various culture and animal models. Reprinted by permission from Springer Nature: Acta Neuropathol, 129(2): 183-206, “Amyloid beta oligomers in Alzheimer’s disease pathogenesis, treatment, and diagnosis” by Viola KL and Klein WL. Copyright 2015 Springer Nature [200].](https://figures.cochat.ai/paper-figures/4c12da5f31934b84a9263cc86d9b1ffd/the-amyloid-oligomer-hypothesis-beginning-of-the-third-decade-figure-2.jpg)

![Fig.4 AβOs can be divided into two classes based on their temporal, spatial, and structural relationships to amyloid plaques as well as their ability to cause memory dysfunction. Type 1 AβOs (aka “peak 1” or HMW) are thought to be associated with memory impairment, while type 2 AβOs (aka “peak 2” or LMW) are not. Only type 2 AβOs are associated with amyloid plaques. Reprinted from “Quaternary Structure Defines a Large Class of Amyloid-beta Oligomers Neutralized by Sequestration” by Liu P, Reed MN, Kotilinek LA, Grant MK, Forster CL, Qiang W, Shapiro SL, Reichl JH, Chiang AC, Jankowsky JL, Wilmot CM, Cleary JP, Zahs KR, and Ashe KH. This was published in Cell Rep, 2015, 11(11): 1760-1771, under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License (CC BY NC ND) https://creativecommons.org/licenses/by-nc-nd/4.0/ [119].](https://figures.cochat.ai/paper-figures/c5448ccd6aa14c24a04007d7a6986c4e/the-amyloid-oligomer-hypothesis-beginning-of-the-third-decade-figure-4.jpg)
![Fig.5 Only high-molecular weight AβOs are capable of binding cultured hippocampal neurons. Synthetic AβOs were divided into high and low molecular weight populations using 50 kDa molecular weight cutoff ultrafiltration (A-B) or size exclusion chromatography (D-F) and incubated with cultured hippocampal neurons. Only high-molecular weight AβOs bind neurons (A, E); no binding of low-molecular weight AβOs was evident (B, F). Scale bar = 40μm. Reprinted from “Synaptic targeting by Alzheimer’s-related amyloid beta oligomers” by Lacor PN, Buniel MC, Chang L, Fernandez SJ, Gong Y, Viola KL, Lambert MP, Velasco PT, Bigio EH, Finch CE, Krafft GA, and Klein WL. This was published in J Neurosci, 2004, 24(45): 10191-10200, copyright 2004; permission conveyed through Copyright Clearance Center, Inc. [16].](https://figures.cochat.ai/paper-figures/16de889766c74140a8a5dc196a8cc4d2/the-amyloid-oligomer-hypothesis-beginning-of-the-third-decade-figure-5.jpg)
![Fig.6 PrPc mediates AβO toxicity through mGluR5, Fyn kinase, and NMDARs. Downstream consequences of the pathway include calcium dyshomeostasis, tau hyperphosphorylation, and synaptic dysfunction and loss. Reprinted from “Fyn kinase inhibition as a novel therapy for Alzheimer’s disease” by Nygaard HB, van Dyck CH, and Strittmater SM. This was published in Alzheimers Res Ther, 2014, 6(1): 8, under the terms of the Creative Commons Attribution License (CC BY) [227].](https://figures.cochat.ai/paper-figures/f727ef34b3b345d8b849289bdb182350/the-amyloid-oligomer-hypothesis-beginning-of-the-third-decade-figure-6.jpg)
![Fig.7 AβOs induce membrane re-distribution of NKAα3 subunit resulting its downregulation and excessive Ca++ buildup. A hypothesized early event in AβO-induced neuronal damage is binding to NKAα3 on neuronal membranes, causing restructuring of the NKAα3 docking station into toxic clusters of membrane proteins. Ultimately, this results in downregulation of NKAα3 on the neuronal surface and buildup of toxic Ca++. Adapted and reprinted from “Alzheimer’s Toxic Amyloid Beta Oligomers: Unwelcome Visitors to the Na/K ATPase alpha3 Docking Station” by DiChiara T, DiNunno N, Clark J, Bu RL, Cline EN, Rollins MG, Gong Y, Brody DL, Sligar SG, Velasco PT, Viola KL, and Klein WL. This was published in Yale J Biol Med, 2017, 90(1): 45-61, under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License (CC BY NC ND) https://creativecommons.org/licenses/by-nc-nd/4.0/ [199].](https://figures.cochat.ai/paper-figures/bd05d1a512054c909e16e461e4020c7c/the-amyloid-oligomer-hypothesis-beginning-of-the-third-decade-figure-7.jpg)
![Fig.8 A cumulative hypothesis for the development of sporadic AD. From De Felice, sporadic AD is hypothesized to be the result of the cumulative impact over a life-time of injuries to the brain and peripheral organs that results in increased AβO levels. Reprinted from “Alzheimer’s disease and insulin resistance: translating basic science into clinical applications” by De Felice FG. This was published in JClin Invest, 2013, 123(2): 531-539, under Free access [322].](https://figures.cochat.ai/paper-figures/24020b5bf03e43718e18004cdfcd4325/the-amyloid-oligomer-hypothesis-beginning-of-the-third-decade-figure-8.jpg)
![Fig.9 Putative therapeutic targets of the AβO pathogenic cascade. Including: 1) AβOs themselves; 2) AβO receptors; 3) signaling pathways; or 4) downstream effectors such as tau. Reprinted with permission of PNAS from “Toward a unified therapeutics approach targeting putative amyloid-beta oligomer receptors” by Overk CR and Masliah E. This was published in Proc Natl Acad Sci U S A, 2014, 111(38): 13680-13681 [392].](https://figures.cochat.ai/paper-figures/fd1348f91c8947ff93496ee3a5d93873/the-amyloid-oligomer-hypothesis-beginning-of-the-third-decade-figure-9.jpg)
![Fig.10 Mechanisms of Aβ-targeting phase III drugs in AD clinical trials. Drugs inhibiting AβO formation (A) or downstream consequences of toxic AβOs (B). Reprinted from “Alzheimer’s disease drug development pipeline: 2017” by Cummings J, Garam L, Mortsdorf T, Ritter A, and Zhong K. This was published in Alzheimers Dementia (N Y), 2017, 3(3): 367-384 [393], under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License (CC BY NC ND) https://creativecommons.org/licenses/by-nc-nd/4.0/) [393].](https://figures.cochat.ai/paper-figures/3fe1a59ed5324adab364ba96901a832d/the-amyloid-oligomer-hypothesis-beginning-of-the-third-decade-figure-10.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Soluble Aβ oligomers are the primary neurotoxic substances,131–133”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [131]
The cited source says what the claim attributes to it.
In the citing paper
“Misfolded Aβ and tau proteins accumulate in the AD brain in a neurodegenerative cascade leading to cognitive decline and dementia [4,5,6,7,8,9].”
From Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies (2023) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“The Aβ oligomer hypothesis, supported by in vitro, in vivo, and ex vivo models, points to the toxic Aβ oligomers rather than amyloid plaques as key players in AD pathogenesis [4,5,6,7].”
From Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies (2023) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“Elevated levels of oligomers have been associated with AD, as they are found in AD brains and are considered the most toxic and pathogenic form of Aβ [4,5,6,7,18].”
From Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies (2023) · cites this paper as [6]
In the citing paper
“The alternative “Aβ oligomer hypothesis”, supported by in vitro, in vivo, and ex vivo models, points to the toxic Aβ oligomers (AβO)s rather than amyloid plaques as key players in AD pathogenesis [79,80,81].”
From Role of Oxidative Damage in Alzheimer’s Disease and Neurodegeneration: From Pathogenic Mechanisms to Biomarker Discovery (2021) · cites this paper as [80]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
4 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769
RetractedLarson, M., Sherman, M. A., Amar, F., Nuvolone, M., Schneider, J. A., Bennett, D. A., Aguzzi, A., & Lesné, S. E. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.1858-12.2012 · Cited by 277
RetractedRETRACTED: Cognitive effects of cell-derived and synthetically derived Aβ oligomers
Reed, M. N., Hofmeister, J. J., Jungbauer, L. M., Welzel, A. T., Yu, C., Sherman, M. A., Lesné, S., LaDu, M. J., Walsh, D. M., Ashe, K. H., et al. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.11.007 · Cited by 136
RetractedAmar, F., Sherman, M. A., Rush, T., Larson, M. E., Boyle, G. E., Liu, C., Götz, J., Buisson, A., & Lesné, S. (2017) · Science Signaling · doi:10.1126/scisignal.aal2021 · Cited by 118
RetractedAmyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164
Amyloid plaque core protein in Alzheimer disease and Down syndrome.
Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., & Beyreuther, K. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.12.4245 · Cited by 4,431
Terry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A., & Katzman, R. (1991) · Annals of Neurology · doi:10.1002/ana.410300410 · Cited by 4,397
Meta-Analysis of 74,046 Individuals Identifies 11 New Susceptibility Loci for Alzheimer’s Disease
(EADI), E. A. D. I., Lambert, J.-C., (GERAD), G. A. E. R. I. A. D., Alzheimer's Disease Genetic Consortium (ADGC), (CHARGE), C. F. H. A. A. R. I. G. E., Ibrahim-Verbaas, C. A., Harold, D., Naj, A. C., Sims, R., Bellenguez, C., et al. (2013) · Nature Genetics · doi:10.1038/ng.2802 · Cited by 4,336
Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291
Research works printed but not linked: 4
- Meilandt, 2017, Characterization of the selective in vivo and in vitro binding properties of crenezumab: Insights into crenezumab’s unique mechanism of action, J Prev Alzheimers Dis, 4, 293
- Schneider, 2017, The anti-AB oligomer drug CT1812 for Alzheimer’s: Phase 1B/2A safety trial outcomes, J Prev Alzheimers Dis, 4, 317
- Catalano, 2017, Biomarker outcomes from the phase 1b/2a safety trial of the anti-AB oligomer drug CT1812 in Alzheimer’s patients, J Prev Alzheimers Dis, 4, 401
- Leslie, 2017, Phase II study to assess safety and target engagement of AMX0035, a novel combination therapy, in Alzheimer’s disease, Neurotherapeutics, 14, 825
Cited by
Items 801–867 of 867
Chen, S., Guo, D., Zhu, Y., Xiao, S., Xie, J., Zhang, Z., Hu, Y., Huang, J., Ma, X., Ning, Z., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26692303
Schiff Base Complex rescues mice against scopolamine-induced cognitive dysfunction
Noreen, S., Nazir, R., Khan, M., & Shah, S. A. (2026) · Drug and Chemical Toxicology · doi:10.1080/01480545.2025.2606103
Aβ 42 Adopts a Stronger Binding Affinity to the Gold Surface than Aβ 40
Thai, Q. M., & Ngo, S. T. (2026) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.5c07335
Characterizations of the β-amyloid (Aβ)-membrane interaction intermediates
Kengwerere, M. K., Wang, T., & Qiang, W. (2026) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2026.01.028
Revisiting amyloid aggregation across diseases: Mechanistic insights driven by histidine tautomerism
Salimi, A., Parida, R., Rafiq, F., & Lee, J. Y. (2026) · Bulletin of the Korean Chemical Society · doi:10.1002/bkcs.70123
The influence of the liposomal form of curcumin and microRNA on the course of Alzheimer’s disease
Kot, Y. G., Kot, K., Андріяш, Г. С., Tigunova, O., Blume, Y. B., & Shulga, S. (2025) · Regulatory Mechanisms in Biosystems · doi:10.15421/0225187
Two-photon in vivo imaging of synaptic loss in 5XFAD mouse model of Alzheimer’s disease
Матухно, А. Е., Voynov, V. B., Борисович, Б. И., Evsyukova, E. V., Taisaeva, A. O., Gerasimov, А. S., Surkov, M. S., Ponyatovskaya, A. M., & Kiroy, V. N. (2026) · Discover Neuroscience · doi:10.1186/s13064-026-00250-z
Alzheimer’s Disease Brain Organoids as a Source of Disease-Relevant Amyloid-Beta OligomersPreprint
Zanderigo, E., Fatima, M., Becker, S., & O’Neil, A. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.03.09.710594
Tu, C., Cheng, Z., Szeto, N., Savransky, S., Glinin, T. S., Herberger, A. L., Shoback, D., Sosa, J. A., Vilardaga, J., Koh, J., et al. (2026) · Science Translational Medicine · doi:10.1126/scitranslmed.adz2837
Oh, H., Kim, H., Kang, H., Kwon, D., French, L., Park, Y. H., Youn, Y. C., An, S. S., Kim, S., & Kang, S. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2026.1620991 · Cited by 1
Man, V. H., He, X., Niu, T., Cai, L., Han, F., Nguyen, P. H., & Wang, J. (2026) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6c00003
Molecular mechanisms of action of MT-MMPs involved in the pathogenesis of Alzheimer’s disease
García‐González, L. (2020) · theses.fr (ABES) · doi:10.70675/a04672c0z1f4az472ezbcd5zbea446eac50c
Rôle central des glucocorticoïdes et de leurs récepteurs dans l’étiologie de la Maladie d’Alzheimer
Canet, G. (2020) · theses.fr (ABES) · doi:10.70675/c46cedbczd8bbz4a8eza301z82de5785048c
Valverde, A. (2020) · theses.fr (ABES) · doi:10.70675/f1b70734zf4e3z4870z8fbdz950d831642a7
An RNA interference strategy for the treatment of Alzheimer's disease
Liu, X. (2021) · theses.fr (ABES) · doi:10.70675/35211b03z3b19z478czb3e2z8d35ab2170d6
The Use of Localized Proteomics to Understand the Pathogenesis of Alzheimer's Disease
Pires, G. (2021) · theses.fr (ABES) · doi:10.70675/45826fd6zd2c8z4b3dz91e0za5080544cb17
Thiberge, C. (2023) · theses.fr (ABES) · doi:10.70675/de2fa338z7aecz4991za94eze8b7694a0d22 · Cited by 1
D-sérine : un maillon central de la physiopathologie amyloïde ?
Ploux, E. (2022) · theses.fr (ABES) · doi:10.70675/e7b5bba0z9abcz4325zae71z841a60892f8b
Die Amyloid-Forschung zieht weitere Kreise und nimmt Fahrt auf
Behl, C. (2026) · Springer eBooks · doi:10.1007/978-3-662-72210-7_14
Disruption of calcium homeostasis by β-amyloids: Insights from dynamical models
Dupont, G. (2026) · Current Opinion in Systems Biology · doi:10.1016/j.coisb.2026.100591
Park, E. J., Mun, B.-R., Kim, S. Y., Elangovan, M., Kim, S. B., Choi, W.-S., & Park, W. J. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2026.1720518
Protein Modifications and Quality Control System: Target for Alzheimer’s Disease Therapy
Sheikh, A. M., Yano, S., Tabassum, S., Bhuiya, J., & Nagai, A. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27104266 · Cited by 1
Neri, L., Anderson, C. A., Fallot, L. B., Mannini, B., & Limbocker, R. (2026) · Elsevier eBooks · doi:10.1016/b978-0-323-99507-8.00045-7
Zampar, S., Fricke, M., Kremser, F., Talucci, I., Maric, H. M., Klafki, H., Rostagno, A. A., Jahn, O., Weggen, S., Ghiso, J. A., et al. (2026) · Molecular Neurobiology · doi:10.1007/s12035-026-05912-x
Singh, J. P., Tyagi, A., & ., N. (2026) · International Journal of Pharmacology and Pharmaceutical Sciences · doi:10.33545/26647206.2026.v8.i1a.42
Carrasco, M., Guzman, L., Barroso, E., Olloquequi, J., Cano, A., Ureña, J., Verdaguer, E., Prohens, R., Fortuna, A., Auladell, C., et al. (2026) · GeroScience · doi:10.1007/s11357-026-02321-9
Mitsuoka, Y., Morimoto, T., Bando, K., Hara, S., Fujita, K., & Nishida, K. (2026) · Analytical Chemistry · doi:10.1021/acs.analchem.5c06200
Napolitano, L. (2026) · Firenze University Press eBooks · doi:10.36253/979-12-215-0993-9.05
Napolitano, L. (2026) · Firenze University Press eBooks · doi:10.36253/979-12-215-0993-9.references
Napolitano, L. (2026) · Firenze University Press eBooks · doi:10.36253/979-12-215-0993-9.07
Third Section: Design of a dimeric-nanobody specific for Aβ42 oligomers: the Dimeric-DesAb-O
Napolitano, L. (2026) · Firenze University Press eBooks · doi:10.36253/979-12-215-0993-9.06
Napolitano, L. (2026) · Firenze University Press eBooks · doi:10.36253/979-12-215-0993-9
Napolitano, L. (2026) · Firenze University Press eBooks · doi:10.36253/979-12-215-0993-9.03
Napolitano, L. (2026) · Firenze University Press eBooks · doi:10.36253/979-12-215-0993-9.04
Napolitano, L. (2026) · Firenze University Press eBooks · doi:10.36253/979-12-215-0993-9.02
Conclusion and Future Perspectives
Napolitano, L. (2026) · Firenze University Press eBooks · doi:10.36253/979-12-215-0993-9.08
Fagla, B. M., Zhao, G., Valencia‐Olvera, A. C., Weng, J. M., Rosa, C. D., Ticiani, E., Tai, L. M., Veiga-Lopez, A., & Buhimschi, I. A. (2026) · Placenta · doi:10.1016/j.placenta.2026.06.015
Zhu, Q., Ye, N., Huang, L., Wang, H., Zhao, Q., Ma, L., She, G., Mu, L., & Shi, W. (2026) · Talanta · doi:10.1016/j.talanta.2026.130250
Couto, C. D. O. P., das Eiras, M. L. H., de Morais, J. L. J., Júnior, C. W. L. C., Forlenza, O. V., & de Paula, V. D. J. R. (2026) · Molecular Neurobiology · doi:10.1007/s12035-026-06030-4
Small Molecules as Anti-Alzheimer’s Scaffolds
Hazra, R., Roy, S., Gayen, S., Parui, A., Arshad, A., Roy, N., & Sarkar, A. N. (2026) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9798898815646126010013
Kasongo, A. A., Bhunu, B., Boucher, D. M., Vijithakumar, V., Aly, S. H., Emerton, C., Rousseaux, M. W. C., Lagace, D. C., & Ouimet, M. (2026) · Neuroscience Letters · doi:10.1016/j.neulet.2026.138682
3D nanoscale imaging of amyloid-β oligomer interactions with extracellular vesicles by cryo-ET
Khursheed, A., Shang, Q., Zhang, H., Tian, Y., Szwedziak, P., Volkov, V. A., & Viles, J. H. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2610068123
Jia, M., Mei, J., Guan, Y., Wang, Z., & Ai, H. (2026) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6c00207
Heme–copper–Aβ mediated dopamine oxidation through self-sustaining redox cycling
Dey, C., Pal, P., Khan, A., & Dey, S. G. (2026) · Chemical Communications · doi:10.1039/d6cc03615e
Protein aggregation in Alzheimer's disease
Kaur, P., Kalra, D., Satija, S., & Sahu, S. K. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-36636-9.00010-1
Lum, B., & Qiang, W. (2026) · Biophysical Chemistry · doi:10.1016/j.bpc.2026.107693
Bhattacharya, A., Manjithaya, R. R., Chickabasaviah, Y. T., & Alladi, P. A. (2026) · Annals of Neurosciences · doi:10.1177/09727531261462296
Amphiphilic modification of human lysozyme enhances its ability to inhibit Aβ42 aggregation
Waku, T., Tokazu, R., Hori, T., Okuda, M., Sugimoto, H., Matsuo, K., & Kobori, A. (2026) · Chemistry Letters · doi:10.1093/chemle/upag146
Riffo-Lepe, N., González-Sanmiguel, J., Meza, I., Saavedra, P., Armijo‐Weingart, L., Zambrano, H., Riquelme, A., Salinas, A. G., Martín, L. S., & Aguayo, L. G. (2026) · Neurobiology of Disease · doi:10.1016/j.nbd.2026.107568
Le cerveau sous le capot : Repenser la mécanique de la maladie d’Alzheimer
Lamontagne‐Caron, R. (2026) · The Conversation · doi:10.64628/aap.9dwxupt7u
Targeting Aberrant Protein-Protein Interactions in Cancer and Neurodegenerative Diseases
Ball, T. D. (2025) · Digital Commons - DU (University of Denver) · doi:10.56902/etdcrp.2025.222
Targeting soluble misfolded oligomers in anti-amyloid research
Vosbein, P., Mao, H., & Lou, C. (2026) · Nature Reviews Chemistry · doi:10.1038/s41570-026-00867-y
de Campos, R. M., Carraro, M. F., Bitencourt, A. L. B., Jerisha, J., Ayon, N. J., Juska, V. B., Pinheiro, N. R., Johnson, E. A., Nowar, R., McGee, J. P., et al. (2026) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2026.113499
Self-citationInside the brain: Rethinking the mechanisms of Alzheimer’s disease
Lamontagne‐Caron, R. (2026) · The Conversation · doi:10.64628/aap.kdxdacgp3
Zhang, Z., Wu, J., Pulgar, I. M. R., Chang, E. H. T., Chai, K., Wang, P., Jiang, S., Li, X., Oishi, K., Smith, G. S., et al. (2026) · Neurology International · doi:10.3390/neurolint18090177
Addo, A., Li, B., Murikinati, S. R., Gardner, R., & Zhao, L.-R. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2026.1705436
Lee, M., Lee, S., Kim, J. H., & Oh, M. S. (2026) · Neurochemical Research · doi:10.1007/s11064-026-04914-4
Kavitha, J. M., Sindhu, K. S., Ramakrishnan, S., Cyriac, J., Abraham, I., & Abi, T. G. (2026) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2026.129977
In vitro comparison of Aβ-targeting SNIPR, synNotch, and TRUCK for programmable transgene expression
Siebrand, C. J., Mayeri, Z., Brown, I., Andersen, J. K., & Walton, C. C. (2026) · Alzheimer s Research & Therapy · doi:10.1186/s13195-026-02237-8
BindingDB (2026) · UC San Diego · doi:10.7270/q2wm1kc7
Ilić, B. S. (2026) · Current Issues in Molecular Biology · doi:10.3390/cimb48111123
Physiological APP processing is required for synaptic plasticity and cognition
Kilian, L., Bengelsdorff, V., Just, J., Stork, S., Galanis, C., Banićević, M., Amrein, I., Back, M., Jungenitz, T., Fellenz, M., et al. (2026) · Cell Death and Disease · doi:10.1038/s41419-026-09378-6
Metadata
- Authors
- Cline, E. N., Bicca, M. A., Viola, K. L., & Klein, W. L.
- Affiliations
- Northwestern University (US)
- Department of Neurobiology, Cognitive Neurology and Alzheimer’s Disease Center, International Institute for Nanotechnology, and Chemistry of Life Processes Institute, Northwestern University, Evanston, IL, USA
- Corresponding author
- Klein, William L.
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2018-06-12
- Volume
- 64
- Issue
- s1
- Pages
- S567-S610
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- PMC
- PMC6004937
- OpenAlex
- W2809078375
- Cited by
- 870
- References
- 457
- Citations by year
- 2026: 72 · 2025: 109 · 2024: 99 · 2023: 133 · 2022: 123 · 2021: 123 · 2020: 119 · 2019: 74 · 2018: 17
- FWCI
- 10.99
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Alzheimer s Disease (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Institute on Aging (R41AG054337, T32AG020506)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- amyloid-beta oligomers, Alzheimer's disease
- MeSH terms
- Alzheimer Disease, Animals, Humans, Models, Neurological, Amyloid beta-Peptides
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.